nach oben

Erschienen in:

12.01.2022 | Review

The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy

verfasst von: Seyed Hossein Aghamiri, Khalil Komlakh, Mehran Ghaffari

Erschienen in: Inflammopharmacology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Diabetes is correlated with organ failures as a consequence of microvascular diabetic complications, including neuropathy, nephropathy, and retinopathy. These difficulties come with serious clinical manifestations and high medical costs. Diabetic neuropathy (DN) is one of the most prevalent diabetes complications, affecting at least 50% of diabetic patients with long disease duration. DN has serious effects on patients’ life since it interferes with their daily physical activities and causes psychological comorbidities. There are some potential risk factors for the development of neuropathic injuries. It has been shown that inflammatory mechanisms play a pivotal role in the progression of DN. Among inflammatory players, TLR2 and TLR4 have gained immense importance because of their ability in recognizing distinct molecular patterns of invading pathogens and also damage-associated molecular patterns (DAMPs) providing inflammatory context for the progression of a wide array of disorders. We, therefore, sought to explore the possible role of TLR2 and TLR4 in DN pathogenesis and if whether manipulating TLRs is likely to be successful in fighting off DN.

Aggarwal M, Singh J, Sood S, Arora B (2001) Effects of lisinopril on streptozotocin-induced diabetic neuropathy in rats. Methods amd findings. Exp Clin Pharmacol 23(3):131–134

Aghamiri SH, Komlakh K, Ghaffari M (2021) Toll-like receptors (TLRs) and their potential therapeutic applications in diabetic neuropathy. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2021.108398CrossRefPubMed

Ahuja S, Uniyal A, Akhtar A, Sah SP (2019) Alpha lipoic acid and metformin alleviates experimentally induced insulin resistance and cognitive deficit by modulation of TLR2 signalling. Pharmacol Rep 71(4):614–623. https://doi.org/10.1016/j.pharep.2019.02.016CrossRefPubMed

Alomar SY, Gheit RE, Enan ET, El-Bayoumi KS, Shoaeir MZ, Elkazaz AY, El-Sayed RM (2021) Novel mechanism for memantine in attenuating diabetic neuropathic pain in mice via downregulating the spinal HMGB1/TRL4/NF-kB inflammatory axis. Pharmaceuticals 14(4):307PubMedPubMedCentralCrossRef

Arkan MC, Hevener AL, Greten FR, Maeda S, Li Z-W, Long JM, Karin M (2005) IKK-β links inflammation to obesity-induced insulin resistance. Nat Med 11(2):191–198PubMedCrossRef

Bansal D, Badhan Y, Gudala K, Schifano F (2013) Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J 37(5):375–384PubMedPubMedCentralCrossRef

Bettoni I, Comelli F, Rossini C, Granucci F, Giagnoni G, Peri F, Costa B (2008) Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia 56(12):1312–1319PubMedCrossRef

Biancardi VC, Stranahan AM, Krause EG, de Kloet AD, Stern JE (2016) Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus. Am J Physiol Heart Circ Physiol 310(3):H404-415. https://doi.org/10.1152/ajpheart.00247.2015CrossRefPubMed

Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, Oppenheim JJ (2002) Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298(5595):1025–1029PubMedCrossRef

Bondeva T, Roger T, Wolf G (2007) Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU1 transcriptional sites. Am J Nephrol 27(3):308–314PubMedCrossRef

Brooks B, Delaney-Robinson C, Molyneaux L, Yue DK (2008) Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C β inhibitor, ruboxistaurin. J Diabetes Complications 22(2):88–95PubMedCrossRef

Cameron N, Cotter M, Robertson S (1992) Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 35(1):12–18PubMedCrossRef

Cameron N, Cotter M, Inkster M, Nangle M (2003) Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract 61:S35–S39PubMedCrossRef

Chauhan N, Taliyan R, Sharma PL (2012) Effect of dipyrone and thalidomide alone and in combination on STZ-induced diabetic neuropathic pain. Naunyn Schmiedebergs Arch Pharmacol 385(5):527–538. https://doi.org/10.1007/s00210-011-0724-9CrossRefPubMed

Chawla A, Chawla R, Jaggi S (2016) Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian J Endocrinol Metab 20(4):546–51PubMedPubMedCentralCrossRef

Chen T, Li H, Yin Y, Zhang Y, Liu Z, Liu H (2017) Interactions of Notch1 and TLR4 signaling pathways in DRG neurons of in vivo and in vitro models of diabetic neuropathy. Sci Rep 7(1):1–12

Dange RB, Agarwal D, Masson GS, Vila J, Wilson B, Nair A, Francis J (2014) Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res 103(1):17–27. https://doi.org/10.1093/cvr/cvu067CrossRefPubMed

Dasu MR, Devaraj S, Park S, Jialal I (2010) Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 33(4):861–868PubMedPubMedCentralCrossRef

Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME (2008) Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity 16(6):1248–1255PubMedCrossRef

Davis JE, Braucher DR, Walker-Daniels J, Spurlock ME (2011) Absence of Tlr2 protects against high-fat diet-induced inflammation and results in greater insulin-stimulated glucose transport in cultured adipocytes. J Nutr Biochem 22(2):136–141PubMedCrossRef

De Graaf R, Kloppenburg G, Kitslaar PJ, Bruggeman CA, Stassen F (2006) Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect 8(7):1859–1865PubMedCrossRef

Dennis EA, Norris PC (2015) Eicosanoid storm in infection and inflammation. Nat Rev Immunol 15(8):511–523PubMedPubMedCentralCrossRef

Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I (2008) Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93(2):578–583PubMedCrossRef

Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, Lehuen A (2013) Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 19(1):65–73PubMedCrossRef

Ding Y, Subramanian S, Montes VN, Goodspeed L, Wang S, Han C, Chait A (2012) Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor–deficient mice. Arterioscler Thromb Vasc Biol 32(7):1596–1604PubMedPubMedCentralCrossRef

Elzinga S, Murdock BJ, Guo K, Hayes JM, Tabbey MA, Hur J, Feldman EL (2019) Toll-like receptors and inflammation in metabolic neuropathy; a role in early versus late disease? Exp Neurol 320:112967. https://doi.org/10.1016/j.expneurol.2019.112967CrossRefPubMed

Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105(2):141–150PubMedCrossRef

Feng Q, Liu D, Lu Y, Liu Z (2020) The interplay of Renin-angiotensin system and toll-like receptor 4 in the inflammation of diabetic nephropathy. J Immunol Res 2020:6193407. https://doi.org/10.1155/2020/6193407CrossRefPubMedPubMedCentral

Fessler MB, Rudel LL, Brown M (2009) Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol 20(5):379PubMedPubMedCentralCrossRef

Freshwater JD, Svensson CI, Malmberg AB, Calcutt NA (2002) Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 51(7):2249–2255. https://doi.org/10.2337/diabetes.51.7.2249CrossRefPubMed

Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Abreu MT (2006) Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131(3):862–877. https://doi.org/10.1053/j.gastro.2006.06.017CrossRefPubMed

Gao Y-J, Ji R-R (2010) Chemokines, neuronal–glial interactions, and central processing of neuropathic pain. Pharmacol Ther 126(1):56–68PubMedPubMedCentralCrossRef

Gariboldi S, Palazzo M, Zanobbio L, Selleri S, Sommariva M, Sfondrini L, Rumio C (2008) Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of β-defensin 2 via TLR2 and TLR4. J Immunol 181(3):2103–2110PubMedCrossRef

Guo X, Namekata K, Kimura A, Harada C, Harada T (2017) The renin-angiotensin system regulates neurodegeneration in a mouse model of optic neuritis. Am J Pathol 187(12):2876–2885. https://doi.org/10.1016/j.ajpath.2017.08.012CrossRefPubMed

Hinder LM, Murdock BJ, Park M, Bender DE, O’Brien PD, Rumora AE, Feldman EL (2018) Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: an inflammatory story. Exp Neurol 305:33–43PubMedPubMedCentralCrossRef

Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 271(5249):665–670PubMedCrossRef

Hsu H-C, Hsieh C-L, Wu S-Y, Lin Y-W (2019) Toll-like receptor 2 plays an essential role in electroacupuncture analgesia in a mouse model of inflammatory pain. Acupunct Med 37(6):356–364PubMedCrossRef

Janahi NM, Santos D, Blyth C, Bakhiet M, Ellis M (2015) Diabetic peripheral neuropathy, is it an autoimmune disease? Immunol Lett 168(1):73–79PubMedCrossRef

Jia L, Vianna CR, Fukuda M, Berglund ED, Liu C, Tao C, Lee CE (2014) Hepatocyte Toll-like receptor 4 regulates obesity-induced inflammation and insulin resistance. Nat Commun 5(1):1–11CrossRef

Jialal I, Kaur H, Devaraj S (2014) Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. J Clin Endocrinol Metab 99(1):39–48PubMedCrossRef

Jung UJ, Choi M-S (2014) Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15(4):6184–6223PubMedPubMedCentralCrossRef

Jurga AM, Rojewska E, Piotrowska A, Makuch W, Pilat D, Przewlocka B, Mika J (2016) Blockade of toll-like receptors (TLR2, TLR4) attenuates pain and potentiates buprenorphine analgesia in a rat neuropathic pain model. Neural Plast 2016:5238730PubMedCrossRef

Karumuthil-Melethil S, Perez N, Li R, Vasu C (2008) Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J Immunol 181(12):8323–8334PubMedCrossRef

Kaur S, Pandhi P, Dutta P (2011) Painful diabetic neuropathy: an update. Ann Neurosci 18(4):168PubMedPubMedCentralCrossRef

Keshavarz A, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari SH, Bashash D (2021) Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists. IUBMB Life 73(1):10–25PubMedCrossRef

Kim HS, Han MS, Chung KW, Kim S, Kim E, Kim MJ, Lee MS (2007) Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27(2):321–333. https://doi.org/10.1016/j.immuni.2007.06.010CrossRefPubMed

Krendel DA, Zacharias A, Younger DS (1997) Autoimmune diabetic neuropathy. Neurol Clin 15(4):959–971PubMedCrossRef

Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Ishii A (2012) Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia 55(8):2256–2266PubMedCrossRef

Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Zinkernagel RM (2005) Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11(2):138–145. https://doi.org/10.1038/nm1176CrossRefPubMed

Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Hwang DH (2004) Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 279(17):16971–16979PubMedCrossRef

Lin A, Wang G, Zhao H, Zhang Y, Han Q, Zhang C, Zhang J (2016) TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells. OncoImmunology 5(2):e1074376. https://doi.org/10.1080/2162402X.2015.1074376CrossRefPubMed

Liu X-J, Liu T, Chen G, Wang B, Yu X-L, Yin C, Ji R-R (2016) TLR signaling adaptor protein MyD88 in primary sensory neurons contributes to persistent inflammatory and neuropathic pain and neuroinflammation. Sci Rep 6(1):1–11

Lumeng CN (2013) Innate immune activation in obesity. Mol Aspects Med 34(1):12–29PubMedCrossRef

Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ (1998) Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 352(9145):1978–1981. https://doi.org/10.1016/s0140-6736(98)02478-7CrossRefPubMed

Manschot SM, Gispen WH, Kappelle LJ, Biessels GJ (2003) Nerve conduction velocity and evoked potential latencies in streptozotocin-diabetic rats: effects of treatment with an angiotensin converting enzyme inhibitor. Diabetes Metab Res Rev 19(6):469–477PubMedCrossRef

Matsunaga N, Tsuchimori N, Matsumoto T, Ii M (2011) TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 79(1):34–41PubMedCrossRef

Medeiros R, Figueiredo CP, Pandolfo P, Duarte FS, Prediger RD, Passos GF, Calixto JB (2010) The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav Brain Res 209(1):165–173. https://doi.org/10.1016/j.bbr.2010.01.040CrossRefPubMed

Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Orend G (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15(7):774–780PubMedCrossRef

Mirzamoradi M, Bakhtiyari M, Kimiaee P, Hosseini-Najarkolaei A, Mansournia MA (2015) Investigating the effects of treatment based on single high blood glucose in gestational diabetes screening on maternal and neonatal complications. Arch Gynecol Obstet 292(3):687–695PubMedCrossRef

Mogensen C (2002) The reno-protective role of AT 1-receptor blockers. J Hum Hypertens 16(3):S52–S58PubMedCrossRef

Moriyama H, Wen L, Abiru N, Liu E, Yu L, Miao D, Eisenbarth GS (2002) Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulin self-peptide. Proc Natl Acad Sci USA 99(8):5539–5544. https://doi.org/10.1073/pnas.082120099CrossRefPubMedPubMedCentral

Mu Z-P, Wang Y-G, Li C-Q, Lv W-S, Wang B, Jing Z-H, Ma X-L (2017) Association between tumor necrosis factor-α and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis. Mol Neurobiol 54(2):983–996PubMedCrossRef

Nguyen MA, Favelyukis S, Nguyen A-K, Reichart D, Scott PA, Jenn A, Olefsky JM (2007) A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 282(48):35279–35292PubMedCrossRef

Nickenig G, Harrison DG (2002) The AT1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 105(3):393–396PubMedCrossRef

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Shichiri M (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28(2):103–117PubMedCrossRef

Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Strauss JF (2001) The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276(13):10229–10233PubMedCrossRef

Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Bhattacharya S (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18(8):1279–1285PubMedCrossRef

Pethő G, Reeh PW (2012) Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. Physiol Rev 92(4):1699–1775PubMedCrossRef

Podar T, Tuomilehto J (2002) The role of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in the management of diabetic complications. Drugs 62(14):2007–2012PubMedCrossRef

Quilley J, Santos M, Pedraza P (2011) Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am J Physiol Heart Circ Physiol 300(6):H2316-2322. https://doi.org/10.1152/ajpheart.01259.2010CrossRefPubMedPubMedCentral

Rahimi Z, Moradi M, Nasri H (2014) A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. J Res Med Sci 19(11):1090–1098PubMedPubMedCentral

Ramesh M, Kumari KG, Sudhakar G (2017) The cytokine gene polymorphisms (TNF-α, IL-10 And IFN-γ) and the role of inflammatory cytokines in diabetic neuropathy. Int J Res Med Sci 2(4):1470–1478CrossRef

Reyna SM, Ghosh S, Tantiwong P, Meka CR, Eagan P, Jenkinson CP, Sriwijitkamol A (2008) Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 57(10):2595–2602PubMedPubMedCentralCrossRef

Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31(5):986–1000PubMedPubMedCentralCrossRef

Rice TW, Wheeler AP, Bernard GR, Vincent J-L, Angus DC, Aikawa N, Cao C (2010) A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 38(8):1685–1694PubMedCrossRef

Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Lombardi R (2011) Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 58(5):776–783PubMedCrossRef

Schaefer L, Babelova A, Kiss E, Hausser H-J, Baliova M, Krzyzankova M, Götte M (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Investig 115(8):2223–2233PubMedPubMedCentralCrossRef

Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid–induced insulin resistance. J Clin Investig 116(11):3015–3025PubMedPubMedCentralCrossRef

Shin S, Kim KJ, Chang HJ, Lee BW, Yang WI, Cha BS, Choi D (2013) The effect of oral prostaglandin analogue on painful diabetic neuropathy: a double-blind, randomized, controlled trial. Diabetes Obes Metab 15(2):185–188. https://doi.org/10.1111/dom.12010CrossRefPubMed

Song MJ, Kim KH, Yoon JM, Kim JB (2006) Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 346(3):739–745PubMedCrossRef

Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Holman RR (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321(7258):405–412PubMedPubMedCentralCrossRef

Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Fuller JH (2005) Vascular risk factors and diabetic neuropathy. N Engl J Med 352(4):341–350PubMedCrossRef

Thakur V, Gonzalez M, Pennington K, Chattopadhyay M (2016) Viral vector mediated continuous expression of interleukin-10 in DRG alleviates pain in type 1 diabetic animals. Mol Cell Neurosci 72:46–53. https://doi.org/10.1016/j.mcn.2016.01.006CrossRefPubMed

Thakur V, Sadanandan J, Chattopadhyay M (2020) High-mobility group box 1 protein signaling in painful diabetic neuropathy. Int J Mol Sci 21(3):881PubMedCentralCrossRef

Tian J, Song T, Wang H, Wang W, Ma X, Hu Y (2021) Toll-like receptor 2 antagonist ameliorates type 2 diabetes mellitus associated neuropathic pain by repolarizing pro-inflammatory macrophages. Neurochem Res 46(9):2276–2284PubMedCrossRef

Tong PC, Kong AP, So W-Y, Ng MH, Yang X, Ng MC, Chow C-C (2006) Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes. Diabetes Care 29(11):2439–2444PubMedCrossRef

Toyota T, Hirata Y, Ikeda Y, Matsuoka K, Sakuma A, Mizushima Y (1993) Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers. Prostaglandins 46(5):453–468. https://doi.org/10.1016/0090-6980(93)90081-hCrossRefPubMed

Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT (2000) Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 49(1):1–7. https://doi.org/10.2337/diabetes.49.1.1CrossRefPubMed

Tsuda M (2016) Microglia in the spinal cord and neuropathic pain. J Diabetes Investig 7(1):17–26PubMedCrossRef

Tükel Ç, Wilson RP, Nishimori JH, Pezeshki M, Chromy BA, Bäumler AJ (2009) Responses to amyloids of microbial and host origin are mediated through toll-like receptor 2. Cell Host Microbe 6(1):45–53PubMedPubMedCentralCrossRef

Vinik AI, Bril V, Kempler P, Litchy WJ, Tesfaye S, Price KL, Group M.S. (2005) Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Therap 27(8):1164–1180CrossRef

Wang W, Wang J (2018) Toll-like receptor 4 (TLR4)/cyclooxygenase-2 (COX-2) regulates prostate cancer cell proliferation, migration, and invasion by NF-κB activation. Med Sci Monit 24:5588–5597. https://doi.org/10.12659/msm.906857CrossRefPubMedPubMedCentral

Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Gerner C (2012) Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23(5):934–947PubMedPubMedCentralCrossRef

West XZ, Malinin NL, Merkulova AA, Tischenko M, Kerr BA, Borden EC, Byzova TV (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467(7318):972–976PubMedPubMedCentralCrossRef

Wolf G (2000) Free radical production and angiotensin. Curr Hypertens Rep 2(2):167–173PubMedCrossRef

Wu J, Yang X, Zhang YF, Zhou SF, Zhang R, Dong XQ, Yu XQ (2009) Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. Inflamm Res 58(8):473–482. https://doi.org/10.1007/s00011-009-0012-zCrossRefPubMed

Wu F-X, Bian J-J, Miao X-R, Huang S-D, Xu X-W, Gong D-J, Yu W-F (2010) Intrathecal siRNA against Toll-like receptor 4 reduces nociception in a rat model of neuropathic pain. Int J Med Sci 7(5):251PubMedPubMedCentralCrossRef

Yao D, Brownlee M (2010) Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 59(1):249–255PubMedCrossRef

Yasuda H, Sonobe M, Yamashita M, Terada M, Hatanaka I, Huitian Z, Shigeta Y (1989) Effect of prostaglandin E1 analogue TFC 612 on diabetic neuropathy in streptozocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes 38(7):832–838. https://doi.org/10.2337/diab.38.7.832CrossRefPubMed

Yorek MA (2018) The potential role of fatty acids in treating diabetic neuropathy. Curr Diab Rep 18(10):86. https://doi.org/10.1007/s11892-018-1046-9CrossRefPubMedPubMedCentral

Zeng J, Xu Y, Shi Y, Jiang C (2018) Inflammation role in sensory neuropathy in Chinese patients with diabetes/prediabetes. Clin Neurol Neurosurg 166:136–140PubMedCrossRef

Zhang Z, Amorosa LF, Coyle SM, Macor MA, Birnbaum MJ, Lee LY, Haimovich B (2016) Insulin-dependent regulation of mTORC2-Akt-FoxO suppresses TLR4 signaling in human leukocytes: relevance to type 2 diabetes. Diabetes 65(8):2224–2234PubMedCrossRef

Zhang C, Ward J, Dauch JR, Tanzi RE, Cheng HT (2018) Cytokine-mediated inflammation mediates painful neuropathy from metabolic syndrome. PLoS ONE 13(2):e0192333PubMedPubMedCentralCrossRef

Zhao Y, Xin Y, Gao J, Teng RY, Chu HC (2015) Analgesic effect of TAK-242 on neuropathic pain in rats. Int J Clin Exp Med 8(7):11202–11207PubMedPubMedCentral

Zhao J, Bi W, Xiao S, Lan X, Cheng X, Zhang J, Zhu L (2019) Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci Rep 9(1):5790. https://doi.org/10.1038/s41598-019-42286-8CrossRefPubMedPubMedCentral

Zhu T, Meng Q, Ji J, Lou X, Zhang L (2015) Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy. Neurosci Lett 585:28–32PubMedCrossRef

Zhu T, Meng Q, Ji J, Zhang L, Lou X (2017) TLR4 and caveolin-1 in monocytes are associated with inflammatory conditions in diabetic neuropathy. Clin Transl Sci 10(3):178–184PubMedCrossRef

Ziegler D, Nowak H, Kempler P, Vargha P, Low P (2004) Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet Med 21(2):114–121PubMedCrossRef

Titel: The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy
verfasst von: Seyed Hossein Aghamiri
Khalil Komlakh
Mehran Ghaffari
Publikationsdatum: 12.01.2022
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 1/2022
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-021-00919-3

The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis

Zur Zeit gratis
COVID-19
Short Communication

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

Zur Zeit gratis
COVID-19
Review

NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?

Zur Zeit gratis
COVID-19
Commentary

Alterations to microbial secretome by estrogen may contribute to sex bias in irritable bowel syndrome

Original Article

Topical phenytoin administration accelerates the healing of acetic acid-induced colitis in rats: evaluation of transforming growth factor-beta, platelet-derived growth factor, and vascular endothelial growth factor

Original Article

Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection

Zur Zeit gratis
COVID-19
Review

Springer Medizin

The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy

Abstract

Weitere Artikel der Ausgabe 1/2022

The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?

Alterations to microbial secretome by estrogen may contribute to sex bias in irritable bowel syndrome

Topical phenytoin administration accelerates the healing of acetic acid-induced colitis in rats: evaluation of transforming growth factor-beta, platelet-derived growth factor, and vascular endothelial growth factor

Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?

Alterations to microbial secretome by estrogen may contribute to sex bias in irritable bowel syndrome

Topical phenytoin administration accelerates the healing of acetic acid-induced colitis in rats: evaluation of transforming growth factor-beta, platelet-derived growth factor, and vascular endothelial growth factor

Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection